"I am glad that taking part in a trial might help others on their own cancer journey.”
A study of GDC-0449 before surgery for pancreatic cancer (HIPPoS)
More about this trial
Researchers were trying to find out more about a new drug called GDC-0449. We know from laboratory research that it can block a type of chemical signalling between cells which may affect the growth of pancreatic cancer.
The aims of the study were to
- See the effect GDC-0449 has on pancreatic cancer and the surrounding healthy tissue
- Learn more about the side effects
Summary of results
This study closed early due to a lack of patients.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor D Tuveson
Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)